Risk of contralateral testicular cancer: A population-based study of 29515 U.S. Men

Journal of the National Cancer Institute

Volumn 97, Issue 14, 2005, Pages 1056-1066

  Fosså, Sophie D ^a   Chen, Jinbo ^b   Schonfeld, Sara J ^b   McGlynn, Katherine A ^b   McMaster, Mary L ^b   Gail, Mitchell H ^b   Travis, Lois B ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; VINBLASTINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RISK; CANCER SURVIVAL; CONFIDENCE INTERVAL; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ORCHIECTOMY; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TESTIS CANCER; UNITED STATES; DYSGERMINOMA; MIDDLE AGED; MORTALITY; MULTIPLE CANCER; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK; RISK ASSESSMENT; SECOND CANCER; SEMINOMA; STATISTICAL MODEL; SURVIVAL; TESTIS TUMOR;

ADULT; CONFIDENCE INTERVALS; DYSGERMINOMA; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, MULTIPLE PRIMARY; NEOPLASMS, SECOND PRIMARY; ODDS RATIO; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SEER PROGRAM; SEMINOMA; SURVIVAL ANALYSIS; TESTICULAR NEOPLASMS; UNITED STATES;

EID: 23244435948     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dji185     Document Type: Article

References (59)

1. Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: A review. J Urol 2003;170:5-11.
2. Doll R, Payne P, Waterhouse J, editors. Cancer incidence in five continents. Vol. 1. Berlin (Germany), Springer-Verlag; 1966.
3. Doll R, Muir C, Waterhouse J, editors. Cancer incidence in five continents. Vol. 2. Berlin (Germany), Spinger-Verlag; 1970.
4. Waterhouse J, Muir C, Correa P, Powell J, editors. Cancer incidence in five continents. Vol. 3. Lyon (France), IARC Scientific Publication No. 15, IARC Press; 1976.
5. Waterhouse J, Muir C, Shanmugaratnam K, Powell J, editors. Cancer incidence in five continents. Vol. 4. Lyon (France), IARC Scientific Publication No. 42, IARC Press; 1982.
6. Muir C, Waterhouse J, Mack T, Powell J, Whelan S, editors. Cancer incidence in five continents. Vol. 5. Lyon (France), IARC Scientific Publication No. 88, IARC Press; 1987.
7. Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell J, editors. Cancer incidence in five continents. Vol. 6. Lyon (France), IARC Scientific Publication No. 120, IARC Press; 1992.
8. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J, editors. Cancer incidence in five continents. Vol. 7. Lyon (France), IARC Scientific Publication No. 143, IARC Press; 1997.
9. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB, editors. Cancer incidence in five continents. Vol. 8. Lyon (France), IARC Scientific Publication No. 155, IARC Press; 2002.
10. Coogan CL, Foster RS, Simmons GR, Tognoni PG, Roth BJ, Donohue JP. Bilateral testicular tumors. Cancer 1998;83:547-52.
11. Che M, Tamboli P, Ro JY, Park DS, Ro JS, Amato RJ, et al. Bilateral testicular germ cell tumors. Cancer 2002;95:1228-33.
12. Holzbeierlein JM, Sogani PC, Sheinfeld J. Histology and clinical outcomes in patients with bilateral testicular germ cell tumors: The Memorial Sloan Kettering Cancer Center experience 1950 to 2001. J Urol 2003;169: 2122-5.
13. Van Leeuwen FE, Stiggelbout AM, Van den Belt-Dusebout AW, Noyon R, Eliel MR, van Kerkhoff EH, et al. Second cancer risk following testicular cancer: A follow-up study of 1,909 patients. J Clin Oncol 1993;11:415-24.
14. Geczi L, Gomez F, Bak M, Bodrogi I. The incidence, prognosis, clinical and histological characteristics, treatment, and outcome of patients with bilateral germ cell testicular cancer in Hungary. J Cancer Res Oncol 2003;129:309-15.
15. Theodore CH, Terrier-Lacombe MJ, Laplanche A, Benoit G, Fizazi K, Stamerra O, et al. Bilateral germ-cell tumours: 22-year experience at the Institut Gustave Roussy Br J Cancer 2004;90:55-9.
16. Osterlind A, Berthelsen JG, Abildgaard N, Hansen SO, Hjalgrim H, Johansen B, et al. Risk of bilateral testicular germ cell cancer in Denmark: 1960-1984. J Natl Cancer Inst 1991;83:1391-5.
17. Hoff Wanderas E, Fossa SD, Tretli S. Risk of a second germ cell cancer after treatment of a primary germ cell cancer in 2201 Norwegian male patients. Eur J Cancer 1997;33:244-52.
18. Dong C, Lonnestedt I, Hemminki K. Familial testicular cancer and second primary cancers in testicular cancer patients by histological type. Eur J Cancer 2001;37:1878-85.
19. Colls BM, Harvey VJ, Skelton L, Thompson PI, Frampton CM. Bilateral germ cell testicular tumors in New Zealand: Experience in Auckland and Christchurch 1978-1994. J Clin Oncol 1996;14:2061-5.
20. Shahab N, Doll DC. Testicular lymphoma. Semin Oncol 1999;26:259-69.
21. Percy C, Van Halden V, Mui C, editors. International classification of diseases for oncology. 2nd edition. WHO: Geneva (Switzerland); 1990.
22. Heidenreich A, Weissbach L, Holtl W, Albers P, Kliesch S, Kohrmann KU, et al. Organ sparing surgery for malignant germ cell tumor of the testis. J Urol 2001;166:2161-5.
23. Steiner H, Holtl L, Maneschg C, Berger AP, Rogatsch H, Bartsch G, et al. Frozen section analysis-guided organ-sparing approach in testicular tumors: Technique, feasibility, and long-term results. Urology 2003;62:508-13.
24. Kennedy BJ, Schmidt JD, Winchester DP, Peace BL, Natarajan N, Mettlin C. National survey of patterns of care for testis cancer. Cancer 1987; 60:1921-30.
25. Kubo H, Shipley WU. Reduction of the scatter dose to the testicle outside the radiation treatment fields. Int J Radiat Oncol Biol Phys 1982;8:1741-5.
26. Warde P, Gospodarowicz MK, Panzarella T, Chow E, Murphy T, Catton CN, et al. Long term outcome and cost in the management of stage I testicular seminoma. Can J Urol 2000;7:967-72.
27. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1997;337: 242-53.
28. Steele GS, Jerome RP, Stewart AK, Menck HR. The National Cancer Data Base report on patterns of care for testicular carcinoma, 1985-1996. Cancer 1999;86:2171-83.
29. Sogani PC, Whitmore WF Jr., Herr HW, Bosl GJ, Golbey RB, Watson RC, et al. Orchiectomy alone in the treatment of clinical stage I nonseminomatous germ cell tumor of the testis. J Clin Oncol 1984;2:267-70.
30. Maier JG, Lee SN. Radiation therapy for nonseminomatous germ cell testicular cancer in adults. Urol Clin North Am 1977;4:477-93.
31. Einhorn LH. Treatment of testicular cancer: A new and improved model. J Clin Oncol 1990;8:1777-81.
32. Peckham M, Barrett A, Liew K, Horwich A, Robinson B, Dobbs HJ, et al. The treatment of metastatic germ cell testicular tumors with bleomycin, etoposide and cisplatin (BEP). Br J Cancer 1983;47:613-9.
33. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
34. Peto R, Peto J. Asymptotically efficient rank invariant procedures. J Am Stat Assoc 1972;135:185-206.
35. Grambsch PM, Therneau TM. "Proportional hazards tests and diagnostics based on weighted residuals (Corr: 95V82 p668)". Biometrika 1994;81: 515-26.
36. National Vital Statistics Reports. Deaths: Final data for 2001. 2003;5: No. 33.
37. Oosterhuis JW, Looijenga LH. Current views on the pathogenesis of testicular germ cell tumours and perspectives for future research: highlights of the 5th Copenhagen workshop on carcinoma in situ and cancer of the testis. APMIS 2003;111:280-9.
38. Martinazzi M, Zampieri A, Martinazzi S, Crivelli F, Mauri MF, Calandra C. Proliferative activity of stage I testicular neoplasms: Evaluation by image analysis of immunoreactive MIB-1. Pathologica 1998;90:783-7.
39. Rapley EA, Crockford GP, Easton DF, Stratton MR, Bishop DT. Localisation of susceptibility genes for familial testicular germ cell tumour. APMIS 2003;111:128-35.
40. Rapley EA, Hockley S, Warren W, Johnson L, Huddart R, Crockford G, et al. Somatic mutations of KIT in familial testicular germ cell tumours. Br J Cancer 2004;90:2397-401.
41. Travis LB, Curtis RE, Storm H, Hall P, Holowaty E, Van Leeuwen FE, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997;89:1429-39.
42. Hartmann JT, Fossa SD, Nichols CR, Droz JP, Horwich A, Gerl A, et al. Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors. J Natl Cancer Inst 2001;93:1733-8.
43. Tabernero J, Paz-Ares L, Salazar R, Lianes P, Guerra JA, Borras J, et al. Incidence of contralateral germ cell testicular tumors in south Europe: Report of the experience at 2 Spanish university hospitals and review of the literature. J Urol 2004;171:164-7.
44. Purdue MP, Deresa SS, Sigurdson AJ, McGlynn KA. International patterns and the trends in testis cancer incidence. Int J Cancer 2005;115:822-7.
45. Christensen TB, Daugaard G, Geertsen PF, von der Maase H. Effect of chemotherapy on carcinoma in situ of the testis. Ann Oncol 1998;9:657-60.
46. Curtis RE, Hankey BF, Myers MH, Young JL Jr. Risk of leukemia associated with the first course of cancer treatment: An analysis of the surveillance, epidemiology, and end results program experience. J Natl Cancer Inst 1984;72:531-44.
47. Pamenter B, De Bono JS, Brown IL, Nandini M, Kaye SB, Russell JM, et al. Bilateral testicular cancer: A preventable problem? Experience from a large cancer centre. Br J Urol Int 2003;92:43-6.
48. Fossa SD, Aass N. Cisplatin-based chemotherapy does not eliminate the risk of a second testicular cancer. Br J Urol 1989;63:531-4.
49. von der Maase H, Meinecke B, Skakkebaek NE. Residual carcinoma-in-situ of contralateral testis after chemotherapy. Lancet 1988;27:477-8.
50. von der Maase H, Rorth M, Walbom-Jorgensen S, Sorensen BL, Christophersen IS, Hald T, et al. Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: Study of 27 cases in 500 patients. Br Med J 1986;293:1398-401.
51. Daugaard G, Giwercman A, Skakkebæk NE. Should the other testis be biopsied? Semin Urol Oncol 1996;14:8-12.
52. Diekmann KP, Loy V. Management of contralateral testicular intraepithelial neoplasia in patients with testicular germ-cell tumor. World J Urol 1994;12:131-5.
53. Meidahl Petersen P, Giwercman A, Daugaard G, Rorth M, Holm Petersen J, Skakkebæk NE, et al. Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis. J Clin Oncol 2002;20:1537-43.
54. Heidenreich A, Moul JW. Contralateral testicular biopsy procedure in patients with unilateral testis cancer: Is it indicated? Semin Urol Oncol 2002;20:234-8.
55. Herr HW, Sheinfeld J. Is biopsy of contralateral testis necessary in patients with germ cell tumors? J Urol 1997;158:1331-4.
56. Lenz S, Skakkebæk NE, Hertel NT. Abnormal ultrasonic pattern in contralateral testes in patients with unilateral testicular cancer. World J Urol 1996;14:55-8.
57. Fossa SD, Opjordsmoen S, Haug E. Androgen replacement and quality of life in patients treated for bilateral testicular cancer. Eur J Cancer 1999;35:1220-5.
58. Harland SJ, Cook PA, Fossa SD, Horwich A, Mead GM, Parkinson MC, et al. Intra-tubular germ cell neoplasia of the contralateral testis in testicular cancer: Defining a high risk group. J Urol 1998;160:1353-7.
59. SEER Stat Database: Incidence-SEER 9 Regs Public-Use, Nov 2003 Sub (1973-2001), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2004, based on the November 2003 submission.